Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&T Committees Would Be Powerful Force Under Medicare Rx

Executive Summary

The recommendations of pharmacy & therapeutics committees would be binding on Medicare prescription drug plans under the proposed implementing regulations for the Part D benefit

You may also be interested in...



Regulating Formularies: OIG Wants Closer Scrutiny of Process; CMS Says Focus on Results

The HHS Inspector General is concerned about lax oversight of conflict-of-interest standards on formulary committees for Medicare Part D plans. CMS is defending its approach, which emphasizes review of the formularies themselves, rather than the process to construct them. For biopharma companies, the “right” regulatory model for formulary oversight is an important issue as health care reform evolves.

P&T Cmtes. Need Incentives To Use Cost-Effectiveness Analyses – MedPAC

Medicare prescription drug plan pharmacy & therapeutics committees should be given incentives for using cost-effectiveness analyses to develop formularies, Medicare Payment Advisory Commission member Alan Nelson suggested during a March 12 meeting in Washington D.C

P&T Cmtes. Need Incentives To Use Cost-Effectiveness Analyses – MedPAC

Medicare prescription drug plan pharmacy & therapeutics committees should be given incentives for using cost-effectiveness analyses to develop formularies, Medicare Payment Advisory Commission member Alan Nelson suggested during a March 12 meeting in Washington D.C

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS044516

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel